These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 7538999)

  • 1. Plasmapheresis combined with interferon: an effective therapy for multiple sclerosis.
    Medenica RD; Mukerjee S; Alonso K; Lazovic G; Huschart T
    J Clin Apher; 1994; 9(4):222-7. PubMed ID: 7538999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon inhibitor factor predicting success of plasmapheresis in patients with multiple sclerosis.
    Medenica RD; Mukerjee S; Huschart T; Corbitt W
    J Clin Apher; 1994; 9(4):216-21. PubMed ID: 7759466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic interferon therapy of multiple sclerosis: the pros.
    Knobler RL
    Neurology; 1988 Jul; 38(7 Suppl 2):58-61. PubMed ID: 3133575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer cell activity in patients with multiple sclerosis: interferon and plasmapheresis.
    Uchida A; Maida EM; Lenzhofer R; Micksche M
    Immunobiology; 1982 Feb; 160(5):392-402. PubMed ID: 6175561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferons in multiple sclerosis. A review of the evidence.
    Panitch HS
    Drugs; 1992 Dec; 44(6):946-62. PubMed ID: 1282865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased levels of antiviral MxA protein in peripheral blood of patients with a chronic disease of unknown etiology.
    Chieux V; Chehadeh W; Hautecoeur P; Harvey J; Wattré P; Hober D
    J Med Virol; 2001 Oct; 65(2):301-8. PubMed ID: 11536237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmapheresis with immunosuppressive drug therapy in progressive multiple sclerosis. A pilot study.
    Khatri BO; Koethe SM; McQuillen MP
    Arch Neurol; 1984 Jul; 41(7):734-8. PubMed ID: 6234867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferons and multiple sclerosis.
    Clanet M; Blancher A; Calvas P; Rascol O
    Biomed Pharmacother; 1989; 43(5):355-60. PubMed ID: 2477075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic apheresis in multiple sclerosis].
    Nomura K
    Nihon Rinsho; 2003 Aug; 61(8):1388-95. PubMed ID: 12962028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of correlation between impaired interferon production and natural killer activity of lymphocytes in multiple sclerosis.
    Stöger I; Tálas M; Benczúr M; Gyódi E; Petrányi GG; Pálffy G; Kotsy B
    Arch Virol; 1982; 71(3):259-65. PubMed ID: 6179500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrasting effects of alpha, beta, and gamma interferons on nonspecific suppressor function in multiple sclerosis.
    Noronha A; Toscas A; Jensen MA
    Ann Neurol; 1992 Jan; 31(1):103-6. PubMed ID: 1371908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
    Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The dynamics of immunological indicators in the treatment of patients with multiple sclerosis with prednisolone combined with plasmapheresis].
    Neretin VIa; Gannushkina IV; Zhirnova IG; Sapfirova VA; Kir'iakov VA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1988; 88(2):17-21. PubMed ID: 3259769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralising and binding anti-interferon-beta-I b (IFN-beta-I b) antibodies during IFN-beta-I b treatment of multiple sclerosis.
    Kivisäkk P; Alm GV; Tian WZ; Matusevicius D; Fredrikson S; Link H
    Mult Scler; 1997 Jun; 3(3):184-90. PubMed ID: 9310964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics of immune cell trafficking in interferon-beta treated multiple sclerosis patients.
    Hartrich L; Weinstock-Guttman B; Hall D; Badgett D; Baier M; Patrick K; Feichter J; Hong J; Ramanathan M
    J Neuroimmunol; 2003 Jun; 139(1-2):84-92. PubMed ID: 12799025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs.
    Khatri BO; McQuillen MP; Harrington GJ; Schmoll D; Hoffmann RG
    Neurology; 1985 Mar; 35(3):312-9. PubMed ID: 3974889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent interferonemia and interferon responses in multiple sclerosis.
    Hertzog PJ; Wright A; Harris G; Linnane AW; Mackay IR
    Clin Immunol Immunopathol; 1991 Jan; 58(1):18-32. PubMed ID: 1701372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis.
    Link J
    Acta Neurol Scand Suppl; 1994; 158():1-58. PubMed ID: 7732782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic effects of interferons: relevance to multiple sclerosis.
    Rudick RA; Ransohoff RM
    Mult Scler; 1995; 1 Suppl 1():S12-6. PubMed ID: 9345391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Plasmapheresis in multiple sclerosis].
    Fuchs S; Pogglitsch H; Ladurner G; Lechner H
    Wien Klin Wochenschr; 1984 Jan; 96(2):67-9. PubMed ID: 6710999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.